Beone Medicines Ltd. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $1.9 billion (+33.8% year over year) and diluted EPS of $0.25. It usually reports 14–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 25, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 26, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 14–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
1,890
+33.8%
|
385
+208.2%
|
0.25
+212.5%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1,705
+29.6%
|
237
+151.3%
|
0.16
+166.7%
|
|
Apr 14, 2026
14 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1,513
+35.5%
|
227
+17802.1%
|
0.15
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1,498
+32.8%
|
67
+143.8%
|
0.04
+140.5%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1,412
+41.0%
|
125
+202.9%
|
0.08
+188.9%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1,315
+41.6%
|
94
+178.3%
|
0.06
+166.7%
|
|
Apr 28, 2025
28 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1,117
+48.6%
|
1
+100.5%
|
0.00
+100.0%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
1,128
+77.8%
|
-152
+58.7%
|
-0.11
+59.8%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ONC (Nasdaq), BEIGF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Basel
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1651308
- Former names
- BeiGene, Ltd. (until May 27, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.